基因多态性对慢性肾脏病患者罗沙司他疗效的影响

doi:10.3969/j.issn.1006-298X.2022.02.006

肾脏病与透析肾移植杂志 ›› 2022, Vol. 31 ›› Issue (2): 133-138.DOI: 10.3969/j.issn.1006-298X.2022.02.006

基因多态性对慢性肾脏病患者罗沙司他疗效的影响

出版日期:2022-04-28 发布日期:2022-04-21

Influence of gene polymorphism on efficacy of roxadustat in patients with chronic kidney disease

Online:2022-04-28 Published:2022-04-21

摘要/Abstract

摘要： 目的：通过观察慢性肾脏病患者细胞色素酶(CYP2C8)及尿苷二磷酸葡萄糖醛酸基转移酶(UGT1A9)基因型,与罗沙司他谷浓度和血红蛋白反应率的关系,探究基因多态性对罗沙司他代谢及贫血疗效的影响。
方法：纳入22例未进入透析治疗、合并肾性贫血的慢性肾脏病患者,通过聚合酶链反应限制性片段长度多态性(PCRRFLP)法检测患者基因型,并检测患者罗沙司他治疗4～8周时的血红蛋白浓度,将血红蛋白较基线值升高≥10 g／L定义为“血红蛋白反应”,以评价罗沙司他的疗效。应用液相色谱串联质谱(LCMS／MS)法检测罗沙司他谷浓度,对比各基因型组患者药物谷浓度差异。分析不同基因分组患者及不同疗效患者间的药物谷浓度差异。
结果：UGT1A9 rs2070959位点AA型患者治疗后血红蛋白升高值及罗沙司他谷浓度均低于AG型(P<005),但两组血红蛋白反应率差异无统计学意义。UGT1A9 rs3832043位点各基因型组患者治疗前后血红蛋白升高值、血红蛋白反应率、平均谷浓度差异均无统计学意义。CYP2C8相关位点未检测出不同基因型。血红蛋白反应组患者罗沙司他谷浓度显著高于无反应组(P<005)。
结论：UGT1A9基因多态性显著影响罗沙司他的贫血疗效及药物谷浓度。罗沙司他的贫血疗效与药物谷浓度有关。

关键词: 肾性贫血, 罗沙司他, 基因多态性

Abstract: Ｏｂｊｅｃｔｉｖｅ：By exploring relationship among CYP2C8 (cytochrome enzyme) and UGT1A9 (uridine diphosphate glucuronyltransferase) genotypes, roxadustat trough concentration and hemoglobin response rate in patients with chronic kidney disease, analyse effect of gene polymorphisms on metabolism of roxadustat and efficacy of anemia.
Ｍｅｔｈｏｄｏｌｏｇｙ：Twentytwo chronic kidney disease patients not receiving dialysis and complicated with renal anemia were enrolled. The genotypes were detected by polymerase chain reactionrestriction fragment length polymorphism (PCRRFLP) method. The hemoglobin concentration of patients after roxadustat treatment for 4～8 weeks was measured, and an increase in hemoglobin of ≥10 g／L from the baseline value was defined as “hemoglobin response”. The trough concentrations of roxadustat were detected by liquid chromatographytandem mass spectrometry (LCMS／MS), and the differences in drug trough concentrations of patients in each genotype group were compared. Drug trough concentrations of patients with different genotype and different efficacy were analyzed.
Ｒｅｓｕｌｔｓ：The elevated hemoglobin values and rosalostat concentrations in UGT1A9 rs2070959 locus AA group were significantly lower than that in AG group (P<005), but there was no difference in hemoglobin response rate between the two groups (P>005). There was no significant difference in hemoglobin elevation before and after treatment, hemoglobin response rate, and mean trough concentration between UGT1A9 rs3832043 locus genotype groups (P>005). No different genotypes were detected at CYP2C8related loci. The trough concentration of roxadustat in hemoglobin response group was significantly higher than that in nonresponse group (P<005).
Ｃｏｎｃｌｕｓｉｏｎ：UGT1A9 gene polymorphism significantly affects efficacy and trough concentration of roxadustat. The anemic efficacy of roxadustat is related to trough concentration of drug.

Key words: renal anemia, roxadustat, genetic polymorphism

陈奎, 马爽, 张丽洁, 蒲薪羽, 武彤, 杨晶, 赵占正, 肖静. 基因多态性对慢性肾脏病患者罗沙司他疗效的影响[J]. 肾脏病与透析肾移植杂志, 2022, 31(2): 133-138.

CHEN Kui, MA Shuang, ZHANG Lijie, PU Xinyu, WU Tong, YANG Jing, ZHAO Zhanzheng, XIAO Jing. Influence of gene polymorphism on efficacy of roxadustat in patients with chronic kidney disease[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2022, 31(2): 133-138.

[1]	成水芹, 周婷婷, 张志宏, 余乐, 陈赟敏, 王芳, 吕桂兰, 王金泉, 俞雨生. 罗沙司他和重组人促红细胞生成素对腹膜透析患者血压及心脑血管并发症的影响[J]. 肾脏病与透析肾移植杂志, 2022, 31(1): 9-14.
[2]	郑光毅, 洪大情, 李贵森, 等. 罗沙司他对不同铁代谢状态维持性血液透析患者贫血的影响[J]. 肾脏病与透析肾移植杂志, 2021, 30(6): 536-540.
[3]	郝传明, 李菁. 脯氨酰羟化酶抑制剂治疗肾性贫血:全新途径,全新挑战[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 203-204.
[4]	董建华, 范文静, 吴边, 黄力, 李川, 樊蓉, 葛永纯. 罗沙司他治疗血液透析患者红细胞生成素低反应性贫血的疗效观察[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 211-216.
[5]	孙凌霜, 薛瑾虹, 魏萌, 史珂慧, 刘华, 许超, 蒋红利. 罗沙司他替代大剂量重组人红细胞生成素治疗维持性血液透析患者贫血的疗效[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 217-221.
[6]	成水芹, 周婷婷, 张志宏, 娄丽璇, 陈赟敏, 王芳, 吕桂兰, 王金泉, 俞雨生. 罗沙司他治疗腹膜透析肾性贫血的有效性及安全性分析[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 222-227.
[7]	康冬,尚进,武峰,白婵,肖静,赵占正. 罗沙司他对初始透析患者肾性贫血的疗效[J]. 肾脏病与透析肾移植杂志, 2020, 29(5): 420-425.
[8]	翟修文，陈朝红，刘志红. IgG抗体Fc片段受体ⅡBI232T基因多态性与自身免疫性疾病[J]. 肾脏病与透析肾移植杂志, 2019, 28(3): 257-261.
[9]	普文申，陶冶. 他克莫司、环孢素与三唑类抗真菌药的代谢及药物相互作用[J]. 肾脏病与透析肾移植杂志, 2019, 28(1): 63-67.
[10]	郝传明，任玥衡. 缺氧诱导因子与慢性肾脏病贫血[J]. 肾脏病与透析肾移植杂志, 2018, 27(2): 151-152.
[11]	刘必成. 缺氧诱导因子稳定剂的临床研究[J]. 肾脏病与透析肾移植杂志, 2018, 27(2): 153-154.
[12]	孙世仁. 铁调素与肾性贫血[J]. 肾脏病与透析肾移植杂志, 2018, 27(2): 155-156.
[13]	赵卫红，裴小华. 铁剂在肾性贫血的应用体会[J]. 肾脏病与透析肾移植杂志, 2018, 27(1): 52-53.
[14]	朱琳，常水，曲振华，等. CYP3A4、CYP3A5和MDR1基因多态性与肾移植受者他克莫司血药浓度的关系[J]. 肾脏病与透析肾移植杂志, 2017, 26(6): 522-527.
[15]	王彩丽\|刘丽萍\|李增艳. 慢性肾脏病与非肌性肌球蛋白重链9基因多态性相关性[J]. 肾脏病与透析肾移植杂志, 2014, 23(5): 418-421.

ISSN 1006-298X CN 32-1425/R

基因多态性对慢性肾脏病患者罗沙司他疗效的影响

Influence of gene polymorphism on efficacy of roxadustat in patients with chronic kidney disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价